This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
15 Jan 2014

Swedish Regulatory Authority Confirm Approval of AirFluSal Forspiro

Vectura Group plc confirms that its partner, Sandoz, has received Swedish marketing authorisation for AirFluSal Forspiro (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). 

 

The product was first approved in Denmark on 18 December 2013 and Germany on 13 January 2014.  The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

 

Sweden has approved the 50–500 µg and 50–250 µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in the same patient group.  The product's safety, efficacy and equivalence have been proven in multiple clinical trials.1,2

 

The receipt of the marketing authorisations in Sweden, Germany and Denmark follows the successful completion of EU decentralised procedures also including Norway for the 50–500 µg and 50–250 µg dosage forms and for the 50–500 µg dosage form Germany, Belgium, Bulgaria, Hungary, Luxembourg and Romania. Vetter will communicate as and when further market approvals are received.

 

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal Forspiro by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.

 

[1] P Kuna, I Gath, U Thyroff-Friesinger, S Jones. Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma.  Submitted ERS - Reference September 2013

[2] Sandoz data on file
 

Related News

  • News Swiss pharma industry warns US tariffs could harm global patient care

    The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.

  • News Understanding the Benefits and Advances of Cleanroom Technology

    In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?

  • News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US

    The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta...
  • News A Day in the Life of a Director of Business Development

    In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global...
  • News Women in Pharma: Our hopes for 2025 and beyond

    Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the...
  • News CPHI Milan 2024 - From the Floor

    Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at...
  • News The BIOSECURE Act: implications for the pharma supply chain

    On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin...
  • News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing

    The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.